Skip to main content
    R

    Revelation Biosciences Inc (REVB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.90
    +0.08 (+2.09%)

    Market Cap: $2.43M

    Last updated: Nov 17, 2026 at 4:25 PM ET

    Revelation Biosciences Inc (REVB) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Revelation Biosciences (REVB) has a market cap of $2.43M. It holds $9.12M more cash than debt, 375.84% of its market cap. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Market Cap$2.43M
    Latest price (Nov 17, 2026)$3.90

    Key Dates

    The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 24, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 85.39% in the quarter ended Sep 30, 2026.

    Shares Outstanding559.60K
    Shares Change (QoQ)-85.39%

    Price Statistics

    The stock is down 84.51% over 52 weeks and trades 22.47% below its 50-day average.

    Beta (1Y)1.70
    52-Week Change-84.51%
    1-Month Change+18.72%
    3-Month Change-49.81%
    6-Month Change-45.91%
    5-Year Change-100.00%
    Total Return (1Y)-84.51%
    Total Return (3Y CAGR)-94.67%
    Total Return (5Y CAGR)-95.15%
    Return vs SPY (1Y)-95.36%
    Max Drawdown (1Y)-89.80%
    Max Drawdown (3Y)-99.99%
    Sharpe Ratio (1Y)-2.05
    Correlation with SPY (1Y)0.26
    50-Day Average$5.03
    200-Day Average$7.26
    52-Week Range$0.47 to $6.93
    RSI (14 Days)43.4
    Average Volume (20 Days)14.59K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.98x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio3.98x
    Quick Ratio3.98x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -168.09% and return on assets is -121.32% over the last 12 months.

    Return on Equity (ROE)-168.09%
    Return on Assets (ROA)-121.32%
    Return on Capital Employed (ROCE)-158.02%
    ROIC (5Y Average)-79.47%

    Scores

    REVB has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$5.85K
    Operating Income-$12.71M
    Pretax Income-$12.16M
    Net Income-$12.16M
    EBITDA-$12.13M
    EBIT-$12.16M
    Reported EPS (TTM)-$11.15

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 72.16% of the $10.02M in total assets.

    Cash and Equivalents$9.12M
    Total Debt$0
    Net Cash$9.12M
    Net Cash Per Share$16.30
    Working Capital$6.94M
    Shareholder Equity$7.23M
    Book Value Per Share$12.93
    Total Assets$10.02M
    Total Liabilities$2.79M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$10.10M
    FCF Per Share-$17.94
    Depreciation and Amortization$29.55K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Dividends and Yields

    REVB does not pay a dividend.

    Buyback Yield0.00%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 1-for-7 reverse split on Oct 20, 2026.

    Last Split DateOct 20, 2026
    Split TypeReverse split
    Split Ratio1:7

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About REVB

    What is REVB's market cap?

    Revelation Biosciences has a market cap of $2.43M.

    How many shares of REVB are outstanding?

    Revelation Biosciences has 559.60K shares outstanding.

    Does REVB pay a dividend?

    No. Revelation Biosciences does not pay a dividend.

    How much debt does REVB have?

    Revelation Biosciences has $0 of total debt and $9.12M of cash and equivalents, a net cash position of $9.12M.